History
Milestones
September – 2015
Company establishment in Jakarta, Indonesia
July – 2016
Factory ground breaking ceremony (building production facilities for lyophilized powder injection and liquid injection)
September – 2016
Starting sales & marketing activities for importation of oncology and immunosuppressant products from CKD, South Korea
December – 2017
Completion of manufacturing construction in Cikarang, Indonesia
September – 2018
Obtaining GMP (Good Manufacturing Practice) certificate from BPOM (Indonesian FDA)
February – 2019
Obtaining Halal certificate from MUI (Indonesian Council of Ulama) with excellent category
July – 2019
Grand opening ceremony and manufacture inauguration with Kemenkes (Indonesian MoH)
First launch of targeted oral oncology product, Leukivec
August – 2020
Obtaining TKDN (Level of Domestic Content ) from Kemenperin (Indonesian MoI)
January – 2021
Starting Local CMO (Contract Manufacturing Organization) business
March – 2021
Signing the contract of exportation with one MENA Country
October – 2021
First exportation shipment to one MENA Country
August 2022
Inspected by SFDA (Saudi Food and Drug Authority) for GMPÂ Compliances
September – 2022
Obtaining BMP (Company Benefit Weight) from Kemenperin (Indonesian MOI)
Obtaining ISO 14001:2015 (Environmental Management System) from SIS (Syndicate of International System) Certifications
Progress of Cytotoxic injection registration in ASEAN and GCC countries
December – 2023
Moving our HQ location to Sudirman Street, central business district in Jakarta
Our Shareholder
Meet CKD OTTO Shareholders
Key partners who support our commitment to pharmaceutical innovation and advances in cancer treatment.
Video Gallery
Historical Journeys
Playlist
5 Videos